Turning Point Brands (TPB) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 net sales rose 2.8% year-over-year to $108.5 million, with adjusted EBITDA up 7% to $27.0 million, marking the highest quarterly EBITDA since Q2 2021.
Zig-Zag and Stoker's segments delivered strong growth, with Zig-Zag net sales up 8% to $50.5 million and Stoker's up 19% to $42.7 million; both brands gained market share.
Net income increased 31% to $13.0 million, with diluted EPS up 28.3% to $0.68 and adjusted net income up 12.2% to $17.2 million.
FRE modern oral nicotine pouch sales grew 76% sequentially, with a new 6mg product launched and national expansion ongoing.
Liquidity remained strong, ending Q2 with $142.2 million in cash and retiring $118.5 million in convertible notes post-quarter.
Financial highlights
Q2 2024 net sales: $108.5 million (+2.8% YoY); adjusted EBITDA: $27.0 million (+7% YoY); gross profit: $53.8 million (+2.6% YoY); gross margin: 49.6%.
Operating income was $22.8 million (+10.8% YoY); net income: $13.0 million (+31% YoY); diluted EPS: $0.68 (+28.3% YoY).
Free cash flow for Q2 2024 was $10.9 million; operating cash flow for the first half was $36.1 million.
Adjusted EBITDA margin for Q2 2024 was approximately 24.9%; LTM Q2 2024 adjusted EBITDA was $102 million with a 25.1% margin.
Ended Q2 with $142.2 million in cash and $58.8 million available under the revolving credit facility.
Outlook and guidance
Full-year 2024 adjusted EBITDA guidance raised to $98–$102 million, up from $95–$100 million, excluding CDS.
CapEx expectation revised down to $11 million for 2024, with reductions due to timing.
Effective income tax rate expected at 23%–26%; Q2 2024 effective tax rate was 25.5%.
Management expects ample liquidity to meet operating requirements after debt retirement.
Latest events from Turning Point Brands
- Modern Oral net sales jumped 266%, driving 29% overall revenue growth and strong 2026 outlook.TPB
Q4 20252 Mar 2026 - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 202415 Jan 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor change, officer liability limits, and executive pay approval.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025 - Modern Oral sales soared 628% year-over-year, driving record Q3 growth and raised guidance.TPB
Q3 202513 Nov 2025